Zambia

Zambia is a small nation in southern Africa. WHO reports that more than two-thirds of the estimated 11 million Zambians live below the national poverty line, and Zambia ranks 90th out of 103 on the United Nations Development Programme (UNDP) Human Poverty Index scale. In addition, Zambia carries a high burden of infectious diseases, including HIV, malaria and tuberculosis (TB). The Central Statistical Office of Zambia estimates that 20% of Zambians are HIV-infected, and according to UNAIDS, the burden of HIV has reduced the projected life expectancy at birth from 60 years (without HIV/AIDS) to 37 years (with HIV/AIDS). Zambia is one of 15 US President's Emergency Plan for AIDS Relief (PEPFAR) focus countries (read 2008 Zambia report). Efforts to provide life saving HIV medications to infected persons, however, have been complicated by "brain drain," the lack of adequately trained health care providers to deliver these complex medications safely and effectively. 

CCGHE RESPONDS

CCGHE has partnered with JHPIEGO, the University of Zambia School of Medicine and the University Teaching Hospital in Lusaka to improve continuing HIV clinical education with a particular interest in updating HIV knowledge among physicians who practice in remote areas.  The goals of CCGHE clinical training efforts in Zambia are twofold: to improve local HIV clinical expertise and to prevent health care worker migration by keeping physicians interested in providing HIV care in Zambia.

CCGHE-ZAMBIA ACTIVITIES

A5288: MULTIOCTAVE, Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure

Post Date: 
2012-07-16
The study is being done to test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the HIV in your blood to see which drugs might work best to lower your HIV infection. see how well combinations of new anti-HIV drugs work to lower HIV infection see if taking...

A5282: A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology-Based Strategy for Prevention of CIN 2+ in HIV-Infected Women

Post Date: 
2011-03-15
The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to prevent cancer of the cervix in women who have HIV. This study will also see if these methods are safe and tolerable in women who have HIV.

P1077BF: Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

Post Date: 
2010-02-02
1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting Maternal and Infant Survival Everywhere (PROMISE) Protocol is a research protocol of the IMPAACT network designed to address in an integrated and comprehensive fashion...

P1077FF: Formula Feeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

Post Date: 
2010-02-02
1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting Maternal and Infant Survival Everywhere (PROMISE) Protocol is a research protocol of the IMPAACT network designed to address in an integrated and comprehensive fashion...

P1060: Phase II, parallel, randomized, clinical trials comparing the responses to initiation of NNRTI-based antiretroviral therapy in HIV-infected infants who have not previously received Single dose Nevirapine for prevention of Mother-to-child HIV...

Post Date: 
2006-03-27
A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been shown to be an effective way of reducing the risk of mother-to-child transmission (MTCT) of HIV. The purpose of this study was to compare the effectiveness of a non-...

Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial

Post Date: 
2016-03-19
Publication: 
The Lancet
Background: Mortality within the first 6 months after initiating antiretroviral therapy is common in resource-limited settings and is often due to tuberculosis in patients with advanced HIV disease. Isoniazid preventive therapy is recommended in HIV-positive adults, but subclinical tuberculosis can...

Taking the long view on CREATE studies' finding

Post Date: 
2014-05-15
Publication: 
The Lancet Infectious Disease
In the past 10 years, the Consortium to Respond Effectively to the AIDS TB Epidemic (CREATE) has done three large trials exploring new strategies to control HIV-related tuberculosis. Recognising that the global strategy for tuberculosis control of a decade ago (mainly directly observed short-course...
Subscribe to RSS - Zambia